A new screen for tuberculosis drug candidates utilizing a luciferase-expressing recombinant Mycobacterium bovis bacillus Calmette-Guéren

Yuriko Ozeki, Masayuki Igarashi, Matsumi Doe, Aki Tamaru, Naoko Kinoshita, Yoshitoshi Ogura, Tomotada Iwamoto, Ryuichi Sawa, Maya Umekita, Shymaa Enany, Yukiko Nishiuchi, Mayuko Osada-Oka, Tetsuya Hayashi, Mamiko Niki, Yoshitaka Tateishi, Masaki Hatano, Sohkichi Matsumoto

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Tuberculosis (TB) is a serious infectious disease caused by a bacterial pathogen. Mortality from tuberculosis was estimated at 1.5 million deaths worldwide in 2013. Development of new TB drugs is needed to not only to shorten the medication period but also to treat multidrug resistant and extensively drug-resistant TB. Mycobacterium tuberculosis (Mtb) grows slowly and only multiplies once or twice per day. Therefore, conventional drug screening takes more than 3 weeks. Additionally, a biosafety level-3 (BSL-3) facility is required. Thus, we developed a new screening method to identify TB drug candidates by utilizing luciferase-expressing recombinant Mycobacterium bovis bacillus Calmette-Guéren (rBCG). Using this method, we identified several candidates in 4 days in a non-BSL-3 facility. We screened 10,080 individual crude extracts derived from Actinomyces and Streptomyces and identified 137 extracts which possessed suppressive activity to the luciferase of rBCG. Among them, 41 compounds inhibited the growth of both Mtb H37Rv and the extensively drug-resistant Mtb (XDR-Mtb) strains. We purified the active substance of the 1904-1 extract, which possessed strong activity toward rBCG, Mtb H37Rv, and XDR-Mtb but was harmless to the host eukaryotic cells. The MIC of this substance was 0.13 ug/ml, 0.5 ug/ml, and 2.0-7.5 ug/ml against rBCG, H37Rv, and 2 XDR-strains, respectively. Its efficacy was specific to acid-fast bacterium except for the Mycobacterium avium intracellular complex. Mass spectrometry and nuclear magnetic resonance analyses revealed that the active substance of 1904-1 was cyclomarin A. To confirm the mode of action of the 1904-1-derived compound, resistant BCG clones were used. Whole genome DNA sequence analysis showed that these clones contained a mutation in the clpc gene which encodes caseinolytic protein, an essential component of an ATP-dependent proteinase, and the likely target of the active substance of 1904-1. Our method provides a rapid and convenient screen to identify an anti-mycobacterial drug.

Original languageEnglish
Article numbere0141658
JournalPloS one
Volume10
Issue number11
DOIs
Publication statusPublished - Nov 1 2015

Fingerprint

Mycobacterium bovis
Mycobacterium tuberculosis
Bacilli
luciferase
Luciferases
tuberculosis
Bacillus
Tuberculosis
drugs
Extensively Drug-Resistant Tuberculosis
Pharmaceutical Preparations
Screening
extracts
Clone Cells
Genes
clones
Actinomyces
screening
Mycobacterium avium Complex
biosafety

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

A new screen for tuberculosis drug candidates utilizing a luciferase-expressing recombinant Mycobacterium bovis bacillus Calmette-Guéren. / Ozeki, Yuriko; Igarashi, Masayuki; Doe, Matsumi; Tamaru, Aki; Kinoshita, Naoko; Ogura, Yoshitoshi; Iwamoto, Tomotada; Sawa, Ryuichi; Umekita, Maya; Enany, Shymaa; Nishiuchi, Yukiko; Osada-Oka, Mayuko; Hayashi, Tetsuya; Niki, Mamiko; Tateishi, Yoshitaka; Hatano, Masaki; Matsumoto, Sohkichi.

In: PloS one, Vol. 10, No. 11, e0141658, 01.11.2015.

Research output: Contribution to journalArticle

Ozeki, Y, Igarashi, M, Doe, M, Tamaru, A, Kinoshita, N, Ogura, Y, Iwamoto, T, Sawa, R, Umekita, M, Enany, S, Nishiuchi, Y, Osada-Oka, M, Hayashi, T, Niki, M, Tateishi, Y, Hatano, M & Matsumoto, S 2015, 'A new screen for tuberculosis drug candidates utilizing a luciferase-expressing recombinant Mycobacterium bovis bacillus Calmette-Guéren', PloS one, vol. 10, no. 11, e0141658. https://doi.org/10.1371/journal.pone.0141658
Ozeki, Yuriko ; Igarashi, Masayuki ; Doe, Matsumi ; Tamaru, Aki ; Kinoshita, Naoko ; Ogura, Yoshitoshi ; Iwamoto, Tomotada ; Sawa, Ryuichi ; Umekita, Maya ; Enany, Shymaa ; Nishiuchi, Yukiko ; Osada-Oka, Mayuko ; Hayashi, Tetsuya ; Niki, Mamiko ; Tateishi, Yoshitaka ; Hatano, Masaki ; Matsumoto, Sohkichi. / A new screen for tuberculosis drug candidates utilizing a luciferase-expressing recombinant Mycobacterium bovis bacillus Calmette-Guéren. In: PloS one. 2015 ; Vol. 10, No. 11.
@article{b3dcb85cc0a247f2a5cb8186ed0a44c3,
title = "A new screen for tuberculosis drug candidates utilizing a luciferase-expressing recombinant Mycobacterium bovis bacillus Calmette-Gu{\'e}ren",
abstract = "Tuberculosis (TB) is a serious infectious disease caused by a bacterial pathogen. Mortality from tuberculosis was estimated at 1.5 million deaths worldwide in 2013. Development of new TB drugs is needed to not only to shorten the medication period but also to treat multidrug resistant and extensively drug-resistant TB. Mycobacterium tuberculosis (Mtb) grows slowly and only multiplies once or twice per day. Therefore, conventional drug screening takes more than 3 weeks. Additionally, a biosafety level-3 (BSL-3) facility is required. Thus, we developed a new screening method to identify TB drug candidates by utilizing luciferase-expressing recombinant Mycobacterium bovis bacillus Calmette-Gu{\'e}ren (rBCG). Using this method, we identified several candidates in 4 days in a non-BSL-3 facility. We screened 10,080 individual crude extracts derived from Actinomyces and Streptomyces and identified 137 extracts which possessed suppressive activity to the luciferase of rBCG. Among them, 41 compounds inhibited the growth of both Mtb H37Rv and the extensively drug-resistant Mtb (XDR-Mtb) strains. We purified the active substance of the 1904-1 extract, which possessed strong activity toward rBCG, Mtb H37Rv, and XDR-Mtb but was harmless to the host eukaryotic cells. The MIC of this substance was 0.13 ug/ml, 0.5 ug/ml, and 2.0-7.5 ug/ml against rBCG, H37Rv, and 2 XDR-strains, respectively. Its efficacy was specific to acid-fast bacterium except for the Mycobacterium avium intracellular complex. Mass spectrometry and nuclear magnetic resonance analyses revealed that the active substance of 1904-1 was cyclomarin A. To confirm the mode of action of the 1904-1-derived compound, resistant BCG clones were used. Whole genome DNA sequence analysis showed that these clones contained a mutation in the clpc gene which encodes caseinolytic protein, an essential component of an ATP-dependent proteinase, and the likely target of the active substance of 1904-1. Our method provides a rapid and convenient screen to identify an anti-mycobacterial drug.",
author = "Yuriko Ozeki and Masayuki Igarashi and Matsumi Doe and Aki Tamaru and Naoko Kinoshita and Yoshitoshi Ogura and Tomotada Iwamoto and Ryuichi Sawa and Maya Umekita and Shymaa Enany and Yukiko Nishiuchi and Mayuko Osada-Oka and Tetsuya Hayashi and Mamiko Niki and Yoshitaka Tateishi and Masaki Hatano and Sohkichi Matsumoto",
year = "2015",
month = "11",
day = "1",
doi = "10.1371/journal.pone.0141658",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - A new screen for tuberculosis drug candidates utilizing a luciferase-expressing recombinant Mycobacterium bovis bacillus Calmette-Guéren

AU - Ozeki, Yuriko

AU - Igarashi, Masayuki

AU - Doe, Matsumi

AU - Tamaru, Aki

AU - Kinoshita, Naoko

AU - Ogura, Yoshitoshi

AU - Iwamoto, Tomotada

AU - Sawa, Ryuichi

AU - Umekita, Maya

AU - Enany, Shymaa

AU - Nishiuchi, Yukiko

AU - Osada-Oka, Mayuko

AU - Hayashi, Tetsuya

AU - Niki, Mamiko

AU - Tateishi, Yoshitaka

AU - Hatano, Masaki

AU - Matsumoto, Sohkichi

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Tuberculosis (TB) is a serious infectious disease caused by a bacterial pathogen. Mortality from tuberculosis was estimated at 1.5 million deaths worldwide in 2013. Development of new TB drugs is needed to not only to shorten the medication period but also to treat multidrug resistant and extensively drug-resistant TB. Mycobacterium tuberculosis (Mtb) grows slowly and only multiplies once or twice per day. Therefore, conventional drug screening takes more than 3 weeks. Additionally, a biosafety level-3 (BSL-3) facility is required. Thus, we developed a new screening method to identify TB drug candidates by utilizing luciferase-expressing recombinant Mycobacterium bovis bacillus Calmette-Guéren (rBCG). Using this method, we identified several candidates in 4 days in a non-BSL-3 facility. We screened 10,080 individual crude extracts derived from Actinomyces and Streptomyces and identified 137 extracts which possessed suppressive activity to the luciferase of rBCG. Among them, 41 compounds inhibited the growth of both Mtb H37Rv and the extensively drug-resistant Mtb (XDR-Mtb) strains. We purified the active substance of the 1904-1 extract, which possessed strong activity toward rBCG, Mtb H37Rv, and XDR-Mtb but was harmless to the host eukaryotic cells. The MIC of this substance was 0.13 ug/ml, 0.5 ug/ml, and 2.0-7.5 ug/ml against rBCG, H37Rv, and 2 XDR-strains, respectively. Its efficacy was specific to acid-fast bacterium except for the Mycobacterium avium intracellular complex. Mass spectrometry and nuclear magnetic resonance analyses revealed that the active substance of 1904-1 was cyclomarin A. To confirm the mode of action of the 1904-1-derived compound, resistant BCG clones were used. Whole genome DNA sequence analysis showed that these clones contained a mutation in the clpc gene which encodes caseinolytic protein, an essential component of an ATP-dependent proteinase, and the likely target of the active substance of 1904-1. Our method provides a rapid and convenient screen to identify an anti-mycobacterial drug.

AB - Tuberculosis (TB) is a serious infectious disease caused by a bacterial pathogen. Mortality from tuberculosis was estimated at 1.5 million deaths worldwide in 2013. Development of new TB drugs is needed to not only to shorten the medication period but also to treat multidrug resistant and extensively drug-resistant TB. Mycobacterium tuberculosis (Mtb) grows slowly and only multiplies once or twice per day. Therefore, conventional drug screening takes more than 3 weeks. Additionally, a biosafety level-3 (BSL-3) facility is required. Thus, we developed a new screening method to identify TB drug candidates by utilizing luciferase-expressing recombinant Mycobacterium bovis bacillus Calmette-Guéren (rBCG). Using this method, we identified several candidates in 4 days in a non-BSL-3 facility. We screened 10,080 individual crude extracts derived from Actinomyces and Streptomyces and identified 137 extracts which possessed suppressive activity to the luciferase of rBCG. Among them, 41 compounds inhibited the growth of both Mtb H37Rv and the extensively drug-resistant Mtb (XDR-Mtb) strains. We purified the active substance of the 1904-1 extract, which possessed strong activity toward rBCG, Mtb H37Rv, and XDR-Mtb but was harmless to the host eukaryotic cells. The MIC of this substance was 0.13 ug/ml, 0.5 ug/ml, and 2.0-7.5 ug/ml against rBCG, H37Rv, and 2 XDR-strains, respectively. Its efficacy was specific to acid-fast bacterium except for the Mycobacterium avium intracellular complex. Mass spectrometry and nuclear magnetic resonance analyses revealed that the active substance of 1904-1 was cyclomarin A. To confirm the mode of action of the 1904-1-derived compound, resistant BCG clones were used. Whole genome DNA sequence analysis showed that these clones contained a mutation in the clpc gene which encodes caseinolytic protein, an essential component of an ATP-dependent proteinase, and the likely target of the active substance of 1904-1. Our method provides a rapid and convenient screen to identify an anti-mycobacterial drug.

UR - http://www.scopus.com/inward/record.url?scp=84956885277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956885277&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0141658

DO - 10.1371/journal.pone.0141658

M3 - Article

C2 - 26571296

AN - SCOPUS:84956885277

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e0141658

ER -